Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8401 to 8415 of 8941 results

  1. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    Discontinued Reference number: GID-TA11109

    Technology appraisal guidance
    Discontinued

  2. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development Reference number: GID-TA11567 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued

  4. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  5. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  6. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  7. Breathlessness

    Discontinued Reference number: GID-NG10387

    NICE guideline
    Discontinued

  8. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  9. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  10. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  11. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  12. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  13. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  14. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  15. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

    Technology appraisal guidance
    Discontinued